P
Pelican Therapeutics
Next generation T Cell Immunotherapy for Cancer
About Pelican Therapeutics
Pelican Therapeutics, a subsidiary of Heat Biologics, is a pioneering biotech company focused on developing first-in-class therapeutics aimed at achieving in vivo regulatory T cell expansion in humans. The company operates in the biopharmaceutical market, targeting both clinical and research sectors. Pelican Therapeutics primarily serves healthcare providers, research institutions, and pharmaceutical companies looking for advanced immunotherapy solutions. The business model revolves around the development and commercialization of novel T cell costimulators, such as their flagship product PTX-35, which selectively stimulates memory CD8 T cells. Revenue is generated through grants, partnerships, and eventual product sales upon regulatory approval. The company has secured significant funding, including a $15.2 million CPRIT grant, to advance its research and development efforts.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Mar 2017 | $0 | — | Scorpius Holdings | ↗ |
| EARLY VC✓Equity / VC | May 2016 | $15M | $61M | Cancer Prevention and Research Institute of Texas (CPRIT) | — |
Growth signals
Latest recorded traffic for Pelican Therapeutics is 60 monthly website visits, down 73.9% over the last three months. Pelican Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Pelican Therapeutics in the Boca Raton ecosystem
The Pelican Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Cancer Prevention and Research Institute of Texas (CPRIT)
Other known investors3 additional known investors
Scorpius Holdings
Technion Israel Institute of Technology
Small Business Innovation Research
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pelican Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pelican Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










